Ask The Expert: Minimal Residual Disease Testing in Melanoma Management

Join us for an insightful webinar exploring the emerging role of minimal residual disease (MRD) testing in melanoma management. This session will provide an overview of MRD testing and its types, share recent data on physician attitudes and adoption of MRD testing, and highlight how experts are integrating MRD testing into melanoma treatment and care.

The webinar will be led by Dr. Beitsch, a surgical oncologist trained at MD Anderson Cancer Center and the John Wayne Cancer Institute, who brings extensive expertise in advancing melanoma care and applying innovative testing approaches in clinical practice.

Don’t miss this opportunity to learn how MRD testing is shaping the future of melanoma management and improving patient outcomes.

About the Speaker:

Dr. Beitsch is a surgical oncologist trained at MD Anderson Cancer Center and the John Wayne Cancer Institute. Over the past 30 years, he has contributed to multiple practice-changing studies in sentinel lymph node biopsy, breast radiation, genomic testing, and breast cancer genetics. In addition to his clinical and research work, he has built and led innovative ventures, including founding Northpoint Cancer Center, establishing Targeted Medical Education, and serving as Chief Science Officer at Medneon, later acquired by Invitae. He recently completed the Emory Chief Medical Officer Program, further strengthening his expertise at the intersection of clinical care, research, and executive leadership.

This Ask the Expert session is sponsored by: